Nash AI, et al. - In this exploratory post hoc analysis, researchers identified patient and disease characteristics during paliperidone palmitate 1-month formulation (PP1M) treatment correlated with greater likelihood of achieving remission after transition to paliperidone palmitate 3-month formulation (PP3M). After 17 weeks of open-label PP1M, patients with clinical stability were randomized to 48 weeks of double-blind PP3M or PP1M treatment. Findings suggested that patients with early clinically significant improvements in symptoms and severity of the disease while establishing a stable dosage of PP1M were more likely to attain remission after transition to PP3M.